Kurzfassung

Primary Objective:
To evaluate the objective response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring fibroblast growth factor receptor (FGFR) 3 mutations or fusions

Primary endpoint:
Objective response rate in subjects with FGFR3 mutations or fusions based on central genomics laboratory results (cohort A). Response will be based on review of scans by a centralized radiological review committee.Primary Objective:
To evaluate the objective response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring fibroblast growth factor receptor (FGFR) 3 mutations or fusions

Primary endpoint:
Objective response rate in subjects with FGFR3 mutations or fusions based on central genomics laboratory results (cohort A). Response will be based on review of scans by a centralized radiological review committee.» weiterlesen» einklappen